A Phase 4 interventional study of Meloxicam in Osteoarthritis, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 34 Years to 74 Years. Per ClinicalTrials.gov, last updated 2014-07-08.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Osteoarthritis by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Boehringer Ingelheim.
Among the 15 studies in Osteoarthritis by Boehringer Ingelheim, this one is one of 4 that started in 1998, is one of 3 in phase 4, and was the 8th registered.
2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.
Browse Osteoarthritis studies →None of the 15 studies in Osteoarthritis by Boehringer Ingelheim is open now. The open studies under Osteoarthritis, anywhere →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 34 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 4 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 80 across 2,239 interventional studies indexed under Osteoarthritis.
Median enrollment 91 across the 7 interventional studies, 400 across the 8 observational. Of the 15 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Osteoarthritis by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To Access the Efficacy and Safety of Meloxicam 7.5mg once daily over a treatment period of 56 days
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
none
Drug: Meloxicam
Also known as: Mobic
Change from baseline in pain on active movement assessed by a 100 mm visual analogue scale (100 mm, VAS)
Time frame: Baseline, 8 weeks after first drug administration
Change from baseline in Lequesne index
Time frame: Baseline, 8 weeks after first drug administration
Change from baseline in physical examination (tenderness)
Time frame: Baseline, 8 weeks after first drug administration
Assessment of significant change from baseline in status according endoscopy
Time frame: Baseline, 8 weeks after first drug administration
Assessment of significant change from baseline in gastrointestinal (GI) symptoms score
Time frame: Baseline, 8 weeks after first drug administration
Assessment of significant change from baseline in laboratory values
Time frame: Baseline, 8 weeks after first drug administration
Number of Patients with Adverse Events
Time frame: Up to 8 weeks after first drug administration
Assessment of significant change from baseline in physical examination (swelling)
Time frame: Baseline, 8 weeks after treatment
No study locations are listed for this record.
The record gives a start of Oct 1998 and a primary completion of Feb 1999. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Meloxicam